Buparlisib
| CAS No. | 944396-07-0 | Cat. No. | BCP02425 |
| Name | Buparlisib | ||
| Synonyms | NVPBKM120; NVP BKM120;NVP-BKM120;NVP-BKM-120;BKM120;BKM-120;BKM 120; | ||
| Formula | C18H21F3N6O2 | M. Wt | 410.39 |
| Description | Buparlisib is an orally bioavailable specific oral inhibitor of the pan-class I phosphatidylinositol 3-kinase (PI3K) family of lipid kinases with potential antineoplastic activity. Buparlisib specifically inhibits class I PI3K in the PI3K/AKT kinase (or protein kinase B) signaling pathway in an ATP-competitive manner, thereby inhibiting the production of the secondary messenger phosphatidylinositol-3,4,5-trisphosphate and activation of the PI3K signaling pathway. This may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents. | ||
| Related Products | 1312445-63-8（Buparlisib Hydrochloride） | ||
| Pathways | PI3K/Akt/mTOR | ||
| Targets | PI3K | ||
|
PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy
Publications Citing of Biochempartner's Buparlisib(CAS:944396-07-0) |
|
PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy
Publications Citing of Biochempartner's Buparlisib(CAS:944396-07-0) |
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.